On July 1-2, DIOPTRA’s partner Protavio Ltd presented the project at the 1st Greek Forum on Cancer, organized by the Hellenic Cancer Federation (ELLOK): an event that provided a holistic view on the subject of tackling cancer, discussing vital topics such as policy, research, and funding strategies.
The forum highlighted how screening programs are crucial in reducing the cancer burden in our society by detecting cancer early when it is most treatable, providing a significant benefit at a minimal cost. A perspective that couldn’t be more aligned with DIOPTRA’s own mission to revolutionise Colorectal Cancer (CRC) screening through the development of novel methods.
Protavio’s key piece to the DIOPTRA puzzle
At the heart of the DIOPTRA project is Protavio’s commitment to leverage their expertise in protein-based biomarkers. The aim of their work within the framework of the project is bold, yet straightforward: to discover and develop an in vitro diagnostic (IVD) protein biomarker panel that would serve as a reliable CRC screening tool, capable of identifying the disease at its early stage. The DIOPTRA project stands at the forefront of a paradigm shift in CRC screening. By harnessing the potential of protein biomarkers, we’re not just developing a tool for early detection; we’re working towards a future where CRC can be identified early, treatment can begin sooner, and lives can be saved.
